Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Express Scripts
Dow
Johnson and Johnson
Mallinckrodt

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

XELODA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Xeloda patents expire, and when can generic versions of Xeloda launch?

Xeloda is a drug marketed by Hoffmann La Roche and is included in one NDA.

The generic ingredient in XELODA is capecitabine. There are twenty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the capecitabine profile page.

US ANDA Litigation and Generic Entry Outlook for Xeloda

A generic version of XELODA was launched as capecitabine by TEVA PHARMS USA on December 13th, 2019.

Drug patent expirations by year for XELODA
Drug Prices for XELODA

See drug prices for XELODA

Recent Clinical Trials for XELODA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sorrento Therapeutics, Inc.Phase 2/Phase 3
Technische Universit├Ąt DresdenPhase 3
Blokhin's Russian Cancer Research CenterPhase 3

See all XELODA clinical trials

Recent Litigation for XELODA

Identify potential future generic entrants

District Court Litigation
Case NameDate
Hoffmann-La Roche Inc. v. Teva Pharmaceuticals USA, Inc.2012-01-03
HOFFMANN-LA ROCHE INC. v. MYLAN INC.2011-06-07
HOFFMANN-LA ROCHE INC. v. TEVA PHARMACEUTICALS USA, INC.2009-10-16

See all XELODA litigation

Pharmacology for XELODA
Synonyms for XELODA
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
361C509
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine
6804DJ8Z9U
958887-39-3
AB0068959
AB01274776_04
AB01274776-01
AB01274776-02
AC1L1U83
AC1Q4KU8
AJ-45659
AK-72933
AKOS015920130
AM84502
AMX10125
AN-16068
BC215614
BCP9000483
BCPP000300
BR-72933
BRD-K61192372-001-08-9
BS-1000
C-20872
C12650
C15H22FN3O6
Capecitabin
capecitabina
CAPECITABINE
Capecitabine (JAN/USAN/INN)
Capecitabine (Xeloda)
Capecitabine [USAN:USP:INN:BAN]
Capecitabine [USAN]
Capecitabine, >=98% (HPLC)
Capecitabine, 99%
Capecitabine, analytical standard
Capecitabine, European Pharmacopoeia (EP) Reference Standard
Capecitabine, Pharmaceutical Secondary Standard; Certified Reference Material
Capecitabine, United States Pharmacopeia (USP) Reference Standard
capecitabinum
Capecitibine
Capiibine
Captabin
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
CAS-154361-50-9
Caxeta
CC-25374
CC0143
CHEBI:31348
CHEMBL1773
CS-0768
CTK0H6126
CYT011
Cytidine, 5'-deoxy-5-fluoro-N-((pentyloxy)carbonyl)-
Cytidine, 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-
D01223
DB01101
DSSTox_CID_26451
DSSTox_GSID_46451
DSSTox_RID_81625
DTXSID3046451
EX-A835
FT-0082472
FT-0601618
FT-0696497
GAGWJHPBXLXJQN-UORFTKCHSA-N
GTPL6799
HSDB 7656
HY-B0016
J-700154
KS-00000E7O
LS-59070
MCULE-2851259722
MLS003915642
MLS004774137
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
n4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
NCGC00164569-01
NCGC00164569-02
Pentyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrim
Pentyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
pentyl 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-ylcarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl]-5-fluoro-2-oxo-pyrimidin-4-yl]carbamate
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate
PubChem21443
Q-200788
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978-000
Ro-091978000
S-3173
s1156
SC-08810
SCHEMBL8153
SMR002530052
SR-01000931255
SR-01000931255-3
ST2413659
Tox21_112198
Tox21_112198_1
UNII-6804DJ8Z9U
Xabine
Xeloda (TN)
Z1741971721
ZINC3806413
Paragraph IV (Patent) Challenges for XELODA
Tradename Dosage Ingredient NDA Submissiondate
XELODA TABLET;ORAL capecitabine 020896 2008-11-10

US Patents and Regulatory Information for XELODA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 AB RX Yes No   Start Trial   Start Trial   Start Trial
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XELODA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998   Start Trial   Start Trial
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998   Start Trial   Start Trial
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998   Start Trial   Start Trial
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Dow
AstraZeneca
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.